Vitamin D and Vascular Health in Children



Status:Completed
Conditions:Obesity Weight Loss, Other Indications, Gastrointestinal
Therapuetic Areas:Endocrinology, Gastroenterology, Other
Healthy:No
Age Range:10 - 18
Updated:1/16/2019
Start Date:August 2013
End Date:August 13, 2018

Use our guide to learn which trials are right for you!

Vitamin D and Vascular Function in Obese Children

In this study, we will test the central hypothesis that enhancement of vitamin D status in
obese and overweight children will improve their vascular health and their cardiovascular
disease (CVD) and metabolic syndrome risk profile.

Our primary objective is to determine, in obese and overweight children aged 10 to 18 years
with vitamin D deficiency (defined as serum 25-hydroxyvitamin D <20 ng/mL), the efficacy of
enhanced vitamin D3 supplementation in improving vascular endothelial function, arterial
stiffness, insulin sensitivity, and metabolic syndrome risk status; and to assess whether
these effects are dose-dependent. As a secondary objective, we will examine the vitamin D
supplementation-induced effect on adipokines and inflammatory markers relevant to CVD risk.
In a double-masked, controlled trial, we will randomize 252 eligible children to receive
either 600 IU (conventional supplementation), or 1000 IU or 2000 IU (enhanced
supplementation) of vitamin D3 daily for 6 months.

Inclusion Criteria:

- Eligible subjects will be 10 to 18 years of age;

- obese or overweight (BMI ≥85th %tile);

- otherwise healthy, and

- have a serum 25(OH)D concentration <20 ng/mL

Children taking multivitamins should be able to hold off their multivitamins during the
course of the study.

Exclusion Criteria:

Children will be excluded if they

- (a) have hepatic or renal disease, metabolic rickets, malabsorptive disorders, primary
hyperparathyroidism, hyperthyroidism, or other chronic disorders that could affect
vitamin D metabolism;

- (b) are receiving treatment with anticonvulsants, systemic glucocorticoids,
pharmacologic doses of vitamin D (≥1000 IU of vitamin D2 or D3 daily),
antihypertensives, vasoactive drugs, antilipidemics, metformin, antipsychotics, or
other oral insulin regulators;

- (c) have cholelithiasis or urolithiasis;

- (d) have type 1 or type 2 diabetes; or

- (e) have a condition or underlying abnormality that could compromise the safety of the
subject.

Post-menarchial girls with a positive pregnancy test at randomization, or subjects found
during the screening phase to have hypercalcemia (serum calcium >10.8 mg/dL) or significant
fasting hyperglycemia (fasting blood glucose ≥ 125 mg/dL) will also be excluded.
We found this trial at
1
site
Pittsburgh, Pennsylvania 15213
Principal Investigator: Kumaravel Rajakumar, MD, MS
?
mi
from
Pittsburgh, PA
Click here to add this to my saved trials